1375465-09-0

Basic information

• Product Name: CNX-2006
• Synonyms: CNX-2006;N-[3-[[2-[[4-[[1-(2-Fluoroethyl)-3-azetidinyl]aMino]-2-Methoxyphenyl]aMino]-5-(trifluoroMethyl)-4-pyriMidinyl]aMino]phenyl]-2-propenaMide;2-Propenamide, N-[3-[[2-[[4-[[1-(2-fluoroethyl)-3-azetidinyl]amino]-2-methoxyphenyl]amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]phenyl]-;CNX 2006 N-[3-[[2-[[4-[[1-(2-Fluoroethyl)-3-azetidinyl]amino]-2-methoxyphenyl]amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]phenyl]-2-propenamide;N-[3-[[2-[[4-[[1-(2-Fluoroethyl)-3-azetidinyl]amino]-2-methoxyphenyl]amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]phenyl]-2-propenamide CNX 2006;CNX-2006, >=98%;N-[3-[[2-[4-[[1-(2-fluoroethyl)azetidin-3-yl]amino]-2-methoxyanilino]-5-(trifluoromethyl)pyrimidin-4-yl]amino]phenyl]prop-2-enamide;N-(3-((2-((4-((1-(2-Fluoroethyl)azetidin-3-yl)amino)-2-methoxyphenyl)amino)-5-(trifluoromethyl
• CAS NO: 1375465-09-0
• Molecular Formula: C26H27F4N7O2
• Molecular Weight: 545.5318928
• Product Categories: Aromatics, Agonist, Heterocycles, Pharmaceuticals, Intermediates & Fine Chemicals;Inhibitors
• Mol File: 1375465-09-0.mol

Chemical Properties

• Appearance: /
• Density: 1.396±0.06 g/cm3(Predicted)
• PKA: 13.23±0.70(Predicted)
• CAS DataBase Reference: CNX-2006(CAS DataBase Reference)
• NIST Chemistry Reference: CNX-2006(1375465-09-0)
• EPA Substance Registry System: CNX-2006(1375465-09-0)

Safety Data

• Hazardous Substances Data: 1375465-09-0(Hazardous Substances Data)

Usage

Uses

Used in Oncology:
CNX-2006 is used as an anticancer agent for the treatment of various types of cancers that harbor EGFR mutations. It works by selectively targeting and inhibiting the mutant EGFR, thereby disrupting the signaling pathways that promote cancer cell growth and proliferation. This selective inhibition can potentially lead to a more targeted and effective treatment option for patients with EGFR-mutated cancers.
Used in Drug Development:
CNX-2006 is also used in the development of new cancer therapies. Its unique mechanism of action and selectivity for mutant EGFR make it a valuable tool for researchers and pharmaceutical companies in the development of novel treatments for EGFR-mutated cancers. By studying the compound's interactions with the target protein and its effects on cancer cells, researchers can gain valuable insights into the development of more effective and targeted cancer therapies.
Used in Drug Delivery Systems:
To enhance the efficacy and bioavailability of CNX-2006, various drug delivery systems can be employed. These systems can help improve the compound's solubility, stability, and targeted delivery to cancer cells, thereby increasing its therapeutic potential. Examples of drug delivery systems that can be used with CNX-2006 include liposomes, nanoparticles, and polymeric carriers.